TMDX — TransMedics Group, Inc.

Summary of TMDX Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $160.8 million, up 32% year-over-year and 12% sequentially.
• U.S. Transplant Revenue: $155 million, reflecting an 11% sequential increase.
• Operating Profit: $21.3 million, representing 13.2% of total revenue.
• Full Year 2025 Revenue: $605.5 million, a 37% increase year-over-year.
• Full Year Operating Profit: $108.6 million, 18% of total revenue.
• Net Income for Q4: $105 million, boosted by an income tax benefit of $83.8 million.
• Cash Position: Ended 2025 with $488.4 million in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Operational Performance: Achieved record transplant volumes with 5,139 OCS transplants in 2025, up from 3,735 in 2024.
• Transplant Logistics: Revenue from transplant logistics services grew 32% year-over-year to $28.6 million in Q4.
• Clinical Programs: Focus on OCS ENHANCE Heart and OCS DENOVO Lung programs, both cleared by the FDA and in various stages of trial activation.
• International Expansion: Plans to launch NOP model in Europe, starting with Italy, which could significantly expand the addressable market.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $727 million and $757 million, representing 20% to 25% growth over 2025.
• Gross Margin Expectations: Anticipated to remain around 60% in the long term, with some near-term pressure due to international expansion.
• Operating Margin Outlook: Expected to contract by approximately 250 basis points in 2026 due to increased investments in clinical programs and infrastructure.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Issues with the ENHANCE Part B trial due to competitors' reluctance to randomize against their static cold storage technology.
• Operational Challenges: Building out logistics infrastructure in Europe may slow initial expansion efforts.
• Seasonality Effects: Anticipation of Q3 seasonality impacting U.S. transplant activities, which could affect revenue.
• Investment Risks: Increased operating expenses due to R&D investments and infrastructure development may pressure margins in the short term.

5. Notable Q&A Insights

• Guidance Philosophy: Management expressed confidence in their revenue guidance, considering both opportunities and challenges.
• Liver Adoption: Anticipated upcoming registry publications could serve as a catalyst for increased liver transplant adoption.
• NOP Connect 2.0: Early results indicate operational efficiencies and improved management through the new digital platform.
• Heart and Lung Trials: Surgeons' feedback on heart trials remains positive, but specific results are pending; lung transplant numbers were low due to centers awaiting FDA approval for DENOVO.
• OPO Environment: Management supports proposed changes to the organ procurement organization (OPO) landscape, viewing it as an opportunity for improved efficiency and transparency.

Overall, TransMedics demonstrated strong growth in Q4 and 2025, with significant strategic initiatives underway, although they face competitive and operational challenges that could impact future performance.